Protara Therapeutics (NASDAQ:TARA) Announces Quarterly Earnings Results

Key Points

• Protara Therapeutics reported a quarterly earnings per share (EPS) of ($0.35), exceeding the consensus estimate of ($0.43) by $0.08.
• The company's stock, trading at $3.10, has experienced significant volatility with a 52-week range of $1.60 to $10.48.
• Several equities analysts have rated Protara Therapeutics with a consensus rating of "Buy" and a price target averaging $20.50.

Protara Therapeutics (NASDAQ:TARA - Get Free Report) issued its quarterly earnings results on Monday. The company reported ($0.35) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.08, Zacks reports.

Protara Therapeutics Stock Performance

Shares of NASDAQ TARA traded down $0.03 during trading hours on Monday, hitting $3.10. The stock had a trading volume of 145,945 shares, compared to its average volume of 336,808. The company has a market capitalization of $119.60 million, a P/E ratio of -1.80 and a beta of 1.42. The firm's 50-day moving average price is $3.12 and its two-hundred day moving average price is $3.64. Protara Therapeutics has a 52 week low of $1.60 and a 52 week high of $10.48.

Institutional Investors Weigh In On Protara Therapeutics

An institutional investor recently raised its position in Protara Therapeutics stock. Geode Capital Management LLC boosted its stake in shares of Protara Therapeutics, Inc. (NASDAQ:TARA - Free Report) by 114.7% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 744,519 shares of the company's stock after purchasing an additional 397,822 shares during the quarter. Geode Capital Management LLC owned about 1.93% of Protara Therapeutics worth $2,256,000 at the end of the most recent quarter. Institutional investors own 38.13% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on TARA shares. Scotiabank started coverage on Protara Therapeutics in a research note on Wednesday, April 16th. They issued a "sector outperform" rating and a $12.00 price target on the stock. Jones Trading raised Protara Therapeutics to a "strong-buy" rating and set a $21.00 price target on the stock in a research note on Thursday, May 22nd. Finally, HC Wainwright reissued a "buy" rating and issued a $23.00 price target on shares of Protara Therapeutics in a research note on Monday, April 28th. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $20.50.

About Protara Therapeutics

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.